secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242007
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reports 50% 6-month PFS for solnerstotug in PD-(L)1 resistant tumors at ESMO 2025
--------------------------------------------------------------------------------

- 6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.
- Complete response in Merkel cell carcinoma patient; duration of response 54+ weeks. Four of six responders had late onset responses (18-54 weeks).
- Favorable safety: only six mild Grade 1 CRS events across all 98 patients; no new safety signals.
- Phase 2 studies planned in 2L NSCLC and Merkel cell carcinoma in 2026, subject to FDA feedback and capital raise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/0001193125-25-242007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/d223319d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer